全球猴痘疫苗和治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球猴痘疫苗和治療市場預計將從2025年的1.2147億美元成長至2034年的3.0423億美元，2026年至2034年的複合年成長率（CAGR）為10.74%。全球猴痘病例的不斷增加引起了人們對全球猴痘疫苗和治療市場的極大關注。多國疫情的爆發凸顯了有效疫苗和抗病毒療法的迫切需求。隨著各國政府和醫療機構致力於控制疫情蔓延，對預防性疫苗和療法的需求也穩定成長。製藥公司和研究機構正大力投資疫苗研發和抗病毒療法，以應對猴痘疫情。目前已有的疫苗（最初是為預防天花而研發的）已被證明對猴痘有效，同時，人們也在探索新的療法以改善疾病管理。公共衛生措施和政府採購計畫也為市場擴張提供了支持。未來，隨著全球對新興感染疾病的監測和應對能力的提升，猴痘疫苗和治療市場預計將持續成長。公眾意識的提高、診斷能力的提升以及對下一代疫苗的持續研究將促進市場發展。政府、醫療機構和製藥公司之間的持續合作將在塑造市場未來方面發揮關鍵作用。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可以根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球猴痘疫苗與治療市場：依產品分類

• 市場分析、洞察與預測
• 疫苗（如 Jynneos/Imvanex、天花疫苗等）
• 藥物（替可比利馬特、布林西多福韋、西多福韋等）
• 牛痘免疫球蛋白（VIG）

第5章 全球猴痘疫苗與治療市場：依性別分類

• 市場分析、洞察與預測
• 男性
• 女士
• 其他

第6章 全球猴痘疫苗與治療藥物市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物

第7章 全球猴痘疫苗和治療市場：依最終用途分類

• 市場分析、洞察與預測
• 醫院
• 專科診所
• 其他

第8章 全球猴痘疫苗和治療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Bavarian Nordic
  • SIGA Technologies
  • Emergent BioSolutions
  • Tonix Pharmaceuticals
  • Chimerix
  • Johnson & Johnson
  • Sanofi
  • Merck & Co
  • Pfizer
  • Moderna
  • AstraZeneca
  • Roche
  • Takeda
  • BioNTech
  • Dynavax Technologies
  • Arbutus Biopharma
  • GeoVax Labs
  • NanoViricides
  • RedHill Biopharma
  • Inovio Pharmaceuticals

The global monkeypox vaccine and treatment market size is expected to reach USD 304.23 Million in 2034 from USD 121.47 Million in 2025, growing at a CAGR of 10.74% during 2026-2034.The global monkeypox vaccine and treatment market has gained considerable attention due to the increasing incidence of monkeypox infections across various regions. The outbreak of the disease in several countries has highlighted the need for effective vaccines and antiviral treatments. As governments and healthcare organizations focus on controlling outbreaks, the demand for preventive vaccines and therapeutic drugs is increasing steadily. Pharmaceutical companies and research institutions are investing heavily in vaccine development and antiviral therapies to address the disease. Existing vaccines originally developed for smallpox have shown effectiveness against monkeypox, while new treatments are being explored to improve disease management. Public health initiatives and government procurement programs are also supporting the expansion of the market. In the future, the monkeypox vaccine and treatment market is expected to grow as global surveillance and preparedness for emerging infectious diseases increase. Rising awareness, improved diagnostic capabilities, and ongoing research into next-generation vaccines will contribute to market development. Continued collaboration between governments, healthcare organizations, and pharmaceutical companies will play a key role in shaping the market's future.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Vaccine (Jynneos/ Imvanex, Smallpox Vaccine, Others)
• Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others)
• Vaccinia Immune Globulin (Vig)

By Gender

• Male
• Female
• Others

By Route Of Administration

• Oral
• Injectable
• By-End-Use
• Hospitals
• Specialty Clinics
• Others

COMPANIES PROFILED

• Bavarian Nordic, SIGA Technologies, Emergent BioSolutions, Tonix Pharmaceuticals, Chimerix, Johnson & Johnson, Sanofi, Merck & Co., Pfizer, Moderna, AstraZeneca, Roche, Takeda, BioNTech, Dynavax Technologies, Arbutus Biopharma, GeoVax Labs, NanoViricides, RedHill Biopharma, Inovio Pharmaceuticals

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Vaccine (Jynneos/ Imvanex, Smallpox Vaccine, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccinia Immune Globulin (Vig) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY GENDER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Gender
• 5.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY BY-END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast By-end-use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MONKEYPOX VACCINE AND TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Gender
  • 8.2.3 By Route Of Administration
  • 8.2.4 By By-end-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Gender
  • 8.3.3 By Route Of Administration
  • 8.3.4 By By-end-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Gender
  • 8.4.3 By Route Of Administration
  • 8.4.4 By By-end-use
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Gender
  • 8.5.3 By Route Of Administration
  • 8.5.4 By By-end-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Gender
  • 8.6.3 By Route Of Administration
  • 8.6.4 By By-end-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MONKEYPOX VACCINE AND TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Bavarian Nordic
  • 10.2.2 SIGA Technologies
  • 10.2.3 Emergent BioSolutions
  • 10.2.4 Tonix Pharmaceuticals
  • 10.2.5 Chimerix
  • 10.2.6 Johnson & Johnson
  • 10.2.7 Sanofi
  • 10.2.8 Merck & Co
  • 10.2.9 Pfizer
  • 10.2.10 Moderna
  • 10.2.11 AstraZeneca
  • 10.2.12 Roche
  • 10.2.13 Takeda
  • 10.2.14 BioNTech
  • 10.2.15 Dynavax Technologies
  • 10.2.16 Arbutus Biopharma
  • 10.2.17 GeoVax Labs
  • 10.2.18 NanoViricides
  • 10.2.19 RedHill Biopharma
  • 10.2.20 Inovio Pharmaceuticals